Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.31 |
| ▸ | BACE1 | P56817 | 1/20 | 0.31 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12013341 | 0.86 | HTT (0.34) | ALDH1A1GPBAR1BACE1BACE2 | |
| SCHEMBL20180664 | 0.86 | HTT (0.34) | ALDH1A1GPBAR1BACE1BACE2 | |
| SCHEMBL20180516 | 0.86 | HTT (0.34) | ALDH1A1GPBAR1BACE1BACE2 | |
| SCHEMBL20180680 | 0.86 | HTT (0.34) | ALDH1A1GPBAR1BACE1BACE2 | |
| SCHEMBL19533069 | 0.86 | HTT (0.34) | ALDH1A1GPBAR1BACE1BACE2 | |
| SCHEMBL23369279 | 0.86 | HTT (0.34) | ALDH1A1GPBAR1BACE1BACE2 | |
| SCHEMBL15791276 | 0.85 | CYP2C19 (0.36) | ALDH1A1GPBAR1 | |
| SCHEMBL21126773 | 0.85 | GPBAR1 (0.31) | ALDH1A1GPBAR1BACE1BACE2 | |
| SCHEMBL24952144 | 0.85 | GPBAR1 (0.31) | ALDH1A1GPBAR1BACE1BACE2 | |
| SCHEMBL19245754 | 0.85 | GPBAR1 (0.31) | ALDH1A1GPBAR1BACE1BACE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3302570-B1 | TRIMALEIMIDE LINKERS AND USES THEREOF | NEWBIO THERAPEUTICS INC (CN) | 2021-03-31 | — | — | EP | disclosed |
| US-10919969-B2 | Anti-CD123 antibodies and conjugates and derivatives thereof | IMMUNOGEN, INC. (US) | 2021-02-16 | — | — | US | disclosed |
| US-20180079819-A1 | ANTI-CD123 ANTIBODIES AND CONJUGATES AND DERIVATIVES THEREOF | IMMUNOGEN, INC. | 2018-03-22 | — | — | US | disclosed |
| US-20170165373-A1 | BCMA ANTIGEN BINDING PROTEINS | AMGEN INC. (US) | 2017-06-15 | — | — | US | disclosed |
| US-9669102-B2 | Cytotoxic benzodiazepine derivatives | IMMUNOGEN, INC. (US) | 2017-06-06 | — | — | US | disclosed |
| US-20160082114-A1 | CYTOTOXIC BENZODIAZEPINE DERIVATIVES | IMMUNOGEN, INC. | 2016-03-24 | — | — | US | disclosed |
| WO-2016036801-A1 | CYTOTOXIC BENZODIAZEPINE DERIVATIVES | IMMUNOGEN, INC. (US) | 2016-03-10 | — | — | WO | disclosed |
| US-9243058-B2 | BCMA antigen binding proteins | AMGEN, INC. (US) | 2016-01-26 | — | — | US | disclosed |
| US-20150344583-A1 | BCMA ANTIGEN BINDING PROTEINS | AMGEN INC. | 2015-12-03 | — | — | US | disclosed |
| US-20140161828-A1 | BCMA ANTIGEN BINDING PROTEINS | AMGEN INC. (US) | 2014-06-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170165373-A1 | BCMA ANTIGEN BINDING PROTEINS | CD79B, BCR, BCDIN3D | ALDH1A1 4500/4885GPBAR1 684/4885BACE1 3075/4885 |
| US-20180079819-A1 | ANTI-CD123 ANTIBODIES AND CONJUGATES AND DERIVATIVES THEREOF | IL23R, CD22, IL2RA | ALDH1A1 1167/4885GPBAR1 971/4885BACE1 3249/4885 |
| US-20150344583-A1 | BCMA ANTIGEN BINDING PROTEINS | CD79B, BCR, BCAP31 | ALDH1A1 4561/4885GPBAR1 796/4885BACE1 3183/4885 |
| US-20160082114-A1 | CYTOTOXIC BENZODIAZEPINE DERIVATIVES | GABRA6, GABBR1, GABRA5 | ALDH1A1 695/4885GPBAR1 213/4885BACE1 2259/4885 |
| US-20140161828-A1 | BCMA ANTIGEN BINDING PROTEINS | CD79B, BCR, BCDIN3D | ALDH1A1 4500/4885GPBAR1 684/4885BACE1 3075/4885 |
| US-10919969-B2 | Anti-CD123 antibodies and conjugates and derivatives thereof | IL23R, CD22, IL2RA | ALDH1A1 1167/4885GPBAR1 971/4885BACE1 3249/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.